Home » Stocks » MORF

Morphic Holding, Inc. (MORF)

Stock Price: $29.59 USD -0.34 (-1.14%)
Updated Jan 21, 2021 12:28 PM EST - Market open
Market Cap 931.57M
Revenue (ttm) 38.71M
Net Income (ttm) -47.08M
Shares Out 30.53M
EPS (ttm) -1.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $29.59
Previous Close $29.93
Change ($) -0.34
Change (%) -1.14%
Day's Open 30.05
Day's Range 29.34 - 30.40
Day's Volume 16,557
52-Week Range 10.84 - 34.55

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

New program demonstrates breadth of MInT platform with the inclusion of activating antibodies against integrin targets New program demonstrates breadth of MInT platform with the inclusion of a...

Invezz - 3 weeks ago

The biotechnology exchange-traded fund SPDR S&P Biotech ETF (NYSE: XBI) is up around 50% in 2020 and Jefferies' managing director Michael Yee says the valuations are not only justified but sus...

Other stocks mentioned: OLMA, SDGR
GlobeNewsWire - 3 weeks ago

WALTHAM, Mass., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D., ...

Zacks Investment Research - 1 month ago

As of late, it has definitely been a great time to be an investor in Morphic Holding (MORF).

GlobeNewsWire - 2 months ago

WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the trea...

GlobeNewsWire - 2 months ago

Initiated p hase 1 clinical trial for MORF-057 with results expected by mid-2021

GlobeNewsWire - 3 months ago

- Data validat e physiologically relevant assay used in MORF-057 Phase 1 studies to measure receptor occupancy of α 4 β 7 integrin - -MORF-057, inhibitor of α 4 β 7 integrin, in development to...

GlobeNewsWire - 3 months ago

First o rally available integrin inhibitor from MInT Platform to enter the clinic MORF-057, inhibitor o f α 4 β 7 integrin , in development to treat i nflammatory bowel disease ...

GlobeNewsWire - 3 months ago

WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the t...

GlobeNewsWire - 4 months ago

WALTHAM, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of...

GlobeNewsWire - 4 months ago

AbbVie to pay Morphic license fee of $20 million, with future potential milestones and royalties

Zacks Investment Research - 5 months ago

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 13.33% and 37.38%, respectively, for the quarter ended June 2020.

GlobeNewsWire - 5 months ago

Company’s first IND accepted by FDA for MORF-057 in IBD Phase 1 study expected to begin in third-quarter 2020 Positive data presented at DDW 2020 further support MORF-057 preclinical profile

Zacks Investment Research - 5 months ago

Morphic Holding, Inc. (MORF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 6 months ago

Receptor occupancy, potency and selectivity data further build MORF-057 preclinical profile as an oral small molecule treatment candidate for IBD

GlobeNewsWire - 7 months ago

WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the ...

GlobeNewsWire - 9 months ago

WALTHAM, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of...

GlobeNewsWire - 11 months ago

Oral presentation at ECCO highlights MORF-057 as a potent, selective and orally available small molecule development candidate

GuruFocus - 1 year ago

Morphic Holding Inc. (NASDAQ:MORF) is one of five fledgling biotechnology companies cited for their potential to develop a drug that generates more than $1 billion in sales, according to an ar...

GlobeNewsWire - 1 year ago

WALTHAM, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of ...

Benzinga - 1 year ago

Morphic Holding, Inc. (NASDAQ: MORF) made its public debut Thursday morning, opening at $18 after being priced at $15 per share.

About MORF

Morphic Holding, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidates in clinical development are MORF-720, a selective oral avß6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC); and MORF-057, a a4ß7 specific integrin inhibitor for the treatment of inflammatory bowel disease (IBD). The company i... [Read more...]

Industry
Biotechnology
IPO Date
Jun 27, 2019
CEO
Dr. Praveen P. Tipirneni M.D.
Employees
87
Stock Exchange
NASDAQ
Ticker Symbol
MORF
Full Company Profile

Financial Performance

In 2019, MORF's revenue was $16.98 million, an increase of 405.57% compared to the previous year's $3.36 million. Losses were -$43.33 million, 81.8% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for MORF stock is "Strong Buy." The 12-month stock price forecast is 41.25, which is an increase of 39.41% from the latest price.

Price Target
$41.25
(39.41% upside)
Analyst Consensus: Strong Buy